About Icon Genetics

Icon Genet­ics GmbH i. L. (Halle/Saale, Ger­many) is the world leader in devel­op­ing and using expres­sion sys­tems for pro­duc­tion of recom­bi­nant pro­teins in green plants. The com­pa­ny has estab­lished a new gen­er­a­tion pro­duc­tion plat­form, mag­nI­CON®, and holds a dom­i­nant patent port­fo­lio com­posed of over 400 grant­ed patents in the field of plant-based expres­sion sys­tems. The mag­nI­CON® plat­form offers an effi­cient tran­sient expres­sion tech­nol­o­gy for recom­bi­nant pro­teins, which address­es speed, yield, pre­ci­sion, expres­sion con­trol, flex­i­bil­i­ty, on demand pro­duc­tion and safe­ty; espe­cial­ly with respect to the reg­u­la­to­ry require­ments for pro­duc­tion of bio­phar­ma­ceu­ti­cals and pro­teins for diag­nos­tic use.  The tech­nol­o­gy is equal­ly suit­able for pro­duc­ing research sam­ples, as well as for the large scale pro­duc­tion of recom­bi­nant pro­teins of inter­est. Icon Genet­ics has built an effi­cient research and devel­op­ment pipeline for a num­ber of bio­phar­ma­ceu­ti­cals includ­ing pre­ven­tive and ther­a­peu­tic vac­cines, as well as recom­bi­nant pro­teins for diag­nos­tic use.
The Icon Genet­ics team has amassed exten­sive knowl­edge of suc­cess­ful per­for­mance in high­ly com­pet­i­tive envi­ron­ments. The com­pa­ny has built its own GMP-cer­ti­fied facil­i­ty for R&D pur­pos­es, and a qual­i­ty con­trol depart­ment. It has also estab­lished a qual­i­ty man­age­ment sys­tem accord­ing to EU GMP guide­lines. Icon Genet­ics is expe­ri­enced in run­ning FDA-approved clin­i­cal tri­als.